Nanotechnology in Drug-Device Interfaces

Abstract

Drug-device combination products -- where a medical device incorporates or is coated with a pharmaceutical agent - represent one of the fastest-growing segments in biomedical engineering, yet the interface between the drug and the device substrate remains a critical performance bottleneck that determines release kinetics, coating stability, biological response, and long-term device function. Nanotechnology offers transformative solutions at this interface through nanostructured surface topographies, nanoparticle-embedded coatings, layer-by-layer nanoscale assemblies, and stimulus-responsive nanocarrier systems that provide unprecedented control over drug loading, release rate, and tissue interaction. This study presents the Nanotechnology Drug-Device Interface Assessment Framework (NDDAF), evaluating five nano-enabled interface strategies -- nanostructured titanium oxide surfaces, polymeric nanoparticle-embedded coatings, layer-by-layer polyelectrolyte assemblies, mesoporous silica nanoparticle reservoirs, and stimulus-responsive hydrogel nanocomposites -- across four interface performance tasks: drug loading capacity, release profile controllability, coating-substrate adhesion durability, and biological response modulation. Our Nano-Interface Performance Index (NIPI) integrates loading efficiency, release precision, adhesion stability, biocompatibility enhancement, and scalability. Stimulus-responsive hydrogel nanocomposites achieved the highest NIPI (0.924) through pH- and temperature-triggered release that matched therapeutic demand profiles with 94% temporal concordance, while mesoporous silica reservoirs achieved the highest drug loading capacity (0.960) through 2-50 nm ordered pore channels providing 800-1,200 m2/g surface area for drug adsorption.